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Abstract
In the United States, adolescent and young adult (AYA) patients with cancer have the lowest 
clinical trial participation rate of all age groups and slower progress in survival improvement than 
younger patients. Ominously, AYA clinical trial participation has been steadily decreasing since 
2010, except in 15–19 year olds and AYAs with acute lymphoblastic leukemia. In order to reverse 
the accrual trend, multiple changes are necessary, including convincing community oncologists to 
pursue clinical trials on behalf of their AYA patients and to have the new National Community 
Oncology Research Program and National Clinical Trials Network lead a coordinated effort to 
increase accrual.
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1 | INTRODUCTION
In the United States, adolescent and young adult (AYA) patients with cancer have the lowest 
participation rate in clinical trials of all age groups, including infants and except for the most 
elderly (over 85 years of age).1 Because acquisition of clinical specimens for translational 
research occurs primarily in the setting of clinical trials at academic medical centers, AYAs 
also have the lowest proportion of specimens available for laboratory and translational 
research.2 A central issue then is to what extent has the lack of clinical trial activity affected 
their rate of survival progress and, if substantial, what to do about it.
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2 | METHODS AND MATERIALS
2.1 | Study cohorts
Incidence, mortality and survival data were obtained from the National Cancer Institute 
(NCI) Surveillance, Epidemiology and End Results (SEER) program.3,4 Population census 
data were obtained from the U.S. government census website.5 The NCI Cancer Therapy 
Evaluation Program (CTEP) sponsors Phase I, II, and III cancer treatment trials conducted 
by the NCI cooperative groups and NCI-designated cancer centers. Accrual data from these 
trials were provided by Nita Seibel and Shanda Finnegan of CTEP. A total of 371,302 
patient entries during 1997–2009 and 57,701 entries during 2010–2015 were compared with 
trends in cancer survival as a function of age.
2.2 | Statistical analysis
Relative survival was used to assess cancer mortality changes over time. Relative survival 
accounts for competing causes of death as the ratio of observed survival among patients with 
cancer to expected survival in the overall population of the same age as computed from life 
tables of mortality in the general population.6 We obtained 5-year relative survival estimates 
with corresponding 95% confidence intervals (CI) using NCI SEER*Stat software program 
version 4.2.0.2.7 Average percent change (APC) in survival rate was either provided by 
SEER, obtained via applying Joinpoint analysis8 provided by the NCI as Join-point 
Regression Program, Version 4.4.0.0,9 or calculated from log values of survival rates as the 
exponential of the linear estimate regressions. The test of APC = 0 and other correlations 
were tested with the ANOVA F-test for regression. All reported P values were two-sided and 
values ≥0.05 were considered not significant (NS).
3 | RESULTS
3.1 | National treatment trial accruals 1997–2015
Figure 1A shows the annual accruals during 2000–2015 onto national treatment trial in 
patients with cancer of AYAs 15–39 years of age by 5-year age intervals. The dip during 
2002–2003 has been attributed to “9–11,”10 after which there was some improvement, 
especially in 15–19 year olds, until 2010. Since then, however, the accrual steadily declined 
in all age groups, especially in 30–49 year olds (52–57% during 2010–2015) and least of all 
in 15–19 year olds (10% during 2010–2015) (Table 1).
Figure 2 depicts for 2000–2014 both the number of clinical trial accruals and the sum 
proportion of 14 cancers that have their peak proportion during the AYA years as a function 
of single patient years of age: AML,CML, Hodgkin lymphoma, non-Hodgkin lymphoma, 
osteosarcoma, Ewing sarcoma fibromatous sarcoma, Kaposi sarcoma, chondrosarcoma, 
melanoma, and cancer of testis, thyroid, nasopharynx, and cervix. These cancers accounted 
for more than 50% of all cancer diagnosed between 15 and 39 years of age, whereas they 
accounted for only 12% in older (age 40+) patients and 24% of the cancers in younger (age 
< 15).3 The lower panel (B) shows that the very cancers that have the highest prevalence in 
AYAs also have hardly had any clinical trial accruals relative to their prevalence and 
virtually no entries between the ages of 20 and 25. The upper panel (A) also shows a distinct 
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adolescent peak in clinical trial accruals consistent with the accrual trends indicated in 
Figure 1A and Table 1.
3.2 | Acute lymphoblastic leukemia since 2000
The greatest effort during the last decade to increase accruals in AYAs was directed at ALL, 
the most common pediatric cancer. New clinical trials in ALL specifically designed for 
AYAs were launched,11–14 the National Comprehensive Cancer Network (NCTN) released 
practice guidelines for ALL,15 and an increasing number of presentations and publications 
on the topic occurred at national meetings and appeared in the peer-reviewed medical 
literature. Figure 1B shows the annual NCI CTEP-sponsored treatment trial accruals for 
ALL during 2000–2015. The dramatic decrease during 2002–2003 occurred after “9–11” in 
2001,10 since which there has been a steady increase, opposite to the trend for all cancers 
(Fig. 1A).
Figure 3 shows that both survival and clinical trial accruals for ALL were inversely 
correlated with age from age 2 to 85 and when analyzed by single years of age, both show a 
dramatic, cliff-like decrease during the older adolescent years. Joinpoint analysis9 of the 5-
year leukemia-specific survival rate for patients with ALL diagnosed during 2000–2014 as a 
function of single year of age identified two inflections, ages 17 and 20, during which the 
survival rate decreased 20% in just 3 years of this age range. This “AYA ALL cliff” 
constituted 26% of the overall decline from 93% at age 5 to 19% at age 70. Joinpoint 
analysis also identifies ages 16 and 24 as the top and bottom of the accrual cliff. The 
superimposed “cliff” patterns strongly suggest that the survival cliff is due in large part to 
the accrual cliff. Other factors such as a switch from pediatric to adult treatment regimens15 
contribute to the survival cliff but the accrual coincidence implicates clinical trial 
participation as a greater factor.16 The inset to Figure 3 shows no correlation of survival 
when the proportion of patients entered on ALL treatment trials was below 10% (gray zone); 
above 10% there is a strong positive correlation with accrual proportion (r2 = 0.87, P < 
10−12).
If for ALL the only increase in treatment trial participation during the last decade occurred 
in the 10–19 year age group, is there evidence of survival prolongation in the age group and 
not in younger or older persons? Figure 4 shows that there has been an acceleration of 
leukemia-specific survival in 10–19 year olds during the years of clinical trial accrual 
increase since 2004 (APC = 2.44, P < 0.0001) that has been greater than in children <10 
years of age and projects that they may have since caught up with the survival rate in 
children. The trend in 10–19 year olds is in striking contrast to no evidence at all for an 
improvementin 20–29year olds since 1989 (APC = 0.33, P = NS).The lack of survival 
improvement in 20–29 year olds corresponds directly and temporally with a negligible 
accrual increase.
4 | DISCUSSION
A prior comparison of the APC in the 5-year cancer-specific survival rate from 1985 to 1999 
and the accrual rate to national cancer treatment trials during 2001–2006 also showed a 
nearly 1:1 correlation over the entire age range16 as observed in this study. A similar pattern 
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was also found with respect to cancer mortality, in patients <40 years of age.16 Patients aged 
20 to 24 had a particularly poor reduction in cancer mortality, as well as the lowest absolute 
number of clinical trial accruals and virtually none among the cancers with the highest 
prevalence during the AYA years. The paradox is that clinical trial accruals have their all-age 
nadir at precisely the peak age prevalence of AYA cancers. These and the current 
observations enable three fundamental conclusions: (1) both survival prolongation and 
mortality reduction in patients with cancer have been directly correlated with clinical trial 
activity; (2) the dependency of survival prolongation on treatment trial accrual has been 
apparent at all ages; (3) AYAs have had the least trial participation and a resultant least 
survival prolongation and mortality reduction, particularly those 20–29 years of age.16
The multiple correlations between national treatment trial accrual and national cancer 
survival rates explain the slower rate of progress in AYAs than in younger and older patients 
and underscore the need to increase both the number of clinical trials available to AYAs with 
cancer and their participation in them. What is clearly ominous, there-fore, is the decline in 
treatment trial accruals since 2000 in older AYAs. The extra effort that has been expended 
successfully on increasing the clinical trial participation of adolescents with cancer17–25 and 
has apparently been successful should be extended to young adults. Reasons for the decline 
are undoubtedly multifactorial but likely include reorganization of the NCI cooperative 
group structure, function, and reimbursement that by 2000 was under development and by 
2014 was replaced with the NCTN. This entailed reducing the number of adult patient 
cooperative groups from 10 to 4 and including both the Children’s Oncology Group (COG) 
and the Canadian clinical trials network, along with some reduction in the total budget spent 
on cooperative group trials. The NCTN explanation is consistent with the lesser decline in 
pediatric patient accrual (Table 1) and NCTN’s less effect on pediatric cooperative group 
structure. Another factor may be the transition of some cooperative group clinical trials to 
the pharmaceutical industry that become more competitive in funding clinical trials and 
providing infrastructure support. To the extent that the latter may have occurred, the 
reduction in overall clinical trial participation by AYAs and older patients may not have been 
as severe as implied in Figure 1. Among AYAs however, these trials are less common since 
AYAs have different cancers (Fig. 2) and, since they are a much smaller population than 
those of older age, fewer drugs are developed for them by the industry.
One explanation for the improvement in older adolescents is the cooperation between COG 
and the adult cooperative groups that study the overlapping AYA age range. In particular, the 
NCTN has formed a specific intergroup committee representing the AYA interests of the 
pediatric and adult cooperative groups. In addition, several of the adult cooperative groups 
have their own AYA committees focused on studying cancers prevalent in the AYAs.
The U.S. Food and Drug Administration (FDA) has recently encouraged the inclusion of 12–
17 year olds on disease- and target-appropriate adult oncology trials.26 An FDA Advisory 
Committee for Pharmaceutical Science and Clinical Pharmacology reviewed this age group 
in 2012 and recommended that adolescent (>12 years) patients be enrolled on trials for adult 
patients without the need for a previously dedicated pharmacokinetic study in them,27 a 
recommendation that has not been enacted. As recently summarized by the FDA,26 inclusion 
of adolescents in adult oncology trials will require the cooperation of investigators, 
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cooperative groups, industry, institutional review boards, and regulatory agencies to 
overcome real and perceived barriers.26 Despite the FDA Advisory Committee 
recommendation, the pharmaceutical industry continues to exclude adolescents from their 
early drug development clinical trials, primarily because of economic disincentives.
It is particularly gratifying to discover that ALL was one of the cancers that benefited from 
the adolescent accrual increment, but it is disappointing to find that the benefit is sharply 
limited at the upper end to age 20. A striking AYA ALL accrual cliff that is coincident with 
an equally striking AYA survival cliff between the ages of 17 and 20 implicates a strong 
need to increase clinical trial activity in 20–29 year olds with ALL, as well as those with 
other types of cancers. Until this is accomplished it is likely that the AYA survival gap will 
persist. One effort in Ontario, Canada is to specifically study the 15–21 year age interval for 
determinants of outcome, including access to clinical trials.28
Another barrier to clinical trials accrual in the AYA years is the referral of patients to centers 
with, or access to, clinical trials. In Utah, with one children’s hospital and one National 
Comprehensive Cancer Network center, the referral of patients with cancer to either center 
dropped from 92% at age 14 to 44% by age 17.29–35 By age 20, 2 of every 3 patients stayed 
in or were referred to private practices and by age 25 less than 30% of the patients were ever 
seen at the academic medical center.29 Thus a “referral cliff” also exists in AYA oncology.
Prior reports have quantitated AYA patient with cancer participation in clinical trials in the 
2–15% range.1,30,31 Multivariate analysis in one study demonstrated that AYA patients with 
the same cancer diagnosis common to pediatric and AYA populations who were treated by 
non-pediatric oncologists were less likely to enroll onto clinical trials.31 Efforts by the 
pediatric oncology research community to recruit more AYAs onto clinical trials have been 
interpreted by some medical oncologists as an attempt to expand the scope of pediatric 
practice. In reality, the pediatric oncologists’ goal is to assist in the provision and conduct of 
such trials, and in aspects of the care of such patients for which they have more extensive 
experience than their medical colleagues. If the survival improvement versus treatment trial 
accrual proportion correlation for ALL (Fig. 3) is generalizable, it may take more than 10% 
accrual proportion of all available AYA patients to achieve significant survival improvement. 
On the other hand, once the accrual exceeds 10%, the gain may be strongly correlated with 
increased participation.
The investigators of the aforementioned study also found that 15 to 19 year-olds had a 
statistically-significant higher participation rate than any 5-year age range between 20 and 
40 years.31 Also apparent was that clinical trial participation varied directly with the quality 
of health insurance, with those having no insurance have a statistically-significant lower rate 
of enrollment compared to those with private insurance.31 The clinical trial participation rate 
was four times higher in the group with private insurance. In the United States, the Patient 
Protection and Affordable Care Act (ACA) required insurance companies to allow 18–25 
year olds to continue to be covered via their parents’ insurance plans. Within 15 months 
after the ACA was passed in September 2010, the number of newly insured AYAs predicted 
that there would be an additional 4,150 AYAs diagnosed to have cancer before their 26th 
birthday who would have been uninsured prior to the ACA.32 By now, 5 years later, that 
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number is well in excess of 15,000. The increase should have allowed more patients of this 
age group to be better able financially to participate in available clinical trials, and thereby 
ultimately improve survival and cure rates. Since the ACA was implemented, the 19–25 year 
age group has had a statistically significantly lower reduction in NCI-sponsored clinical trial 
accruals in comparison to 26–64-year-old Americans who were not supported by this 
provision in the ACA (28% vs. 51% reduction) (Table 1). This discrete age-delimited effect 
indicates that the ACA helped protect this AYA age group from the generalized decline and 
suggests that the 26-year age cutoff should be increased to an older age.33 Another line of 
evidence of the ACA benefit for young AYAs is the observation that uninsured AYAs were 
less likely to enroll in 2006, before the ACA, but not in 2012/2013 after the ACA was 
implemented.34
Many other factors contribute to lack of participation in clinical trials. In addition to 
economic and insurance-based factors, these can be classified as issues of continuity of care 
and philosophy, provider bias, patient/family preferences, and cooperative group and cancer 
center limitations.35 Specific challenges include lack of clinical trials designed for the AYA 
cancer population; referral patterns; the nature and number of AYA-specific medical 
treatment settings available to AYAs; arbitrary and inappropriate age eligibility limitations in 
clinical trials; perception by AYAs that clinical trials are unsafe/more difficult and more 
likely to interfere with long term goals; English as a second language; and the additional 
time and travel commitment required for clinical trial participation.36,37 Of particular 
concern is that more AYAs with cancer remain in their community oncology setting than any 
other age group38 with the possible exception of patients in the most elderly age group (>85 
years). The national community oncology program (previously known as Community 
Clinical Oncology Program and now as the National Community Oncology Research 
Program [NCORP]) has had a progressively lower rate of entering AYAs on clinical trials.38 
Another factor is race/ethnicity, particularly in view of evidence that participation of 
Hispanic, black, and Asian AYAs with cancer worsened from 2006 to 2012/2013.34
Another unfortunate aspect of the accrual gap in 20–30 year olds is the generalizability of 
their clinical trial results based on an enrollment of only 2% of this population to their 
counterparts in the rest of the AYA population.39 Does comparing 2% enrolled in clinical 
trials with a 9–28% “control” population (SEER data) allow generalization to 72–91% of the 
rest of the country? That for ALL survival, the treatment trial accrual proportion had to be at 
least 10% before a correlation was noted (Fig. 3 inset) suggests that treatment trials have to 
enroll 10% or more of eligible patients to have a general impact on survival.
Participation in clinical trials also provides biospecimens that for AYAs, as mentioned 
above, are under-represented in biobank repositories and have thereby restricted translational 
research. Also, as mentioned above, the array of cancers in AYAs is distinctly different from 
that at any other age, and those that appear to be the same as in other age groups are often of 
a different biology. The host (the AYA) is also clearly different in many ways from children 
and older adults, including pharmacokinetics, toxicity profiles, dose tolerance, and fertility 
considerations. The need for translational research is greater and more challenging in AYAs 
than in any other age group.40 Increased availability of treatment trials with laboratory 
correlates and accrual to them are essential to improving the outcome of cancer in AYAs. 
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The lack of tumor and tissue specimens obtained via clinical trials has seriously 
compromised the ability to identify the biologic and histopathologic differences and discover 
specific treatment approaches for AYAs.
These results should not be interpreted to mean that AYAs and other individuals who 
participate in clinical trials have a greater probability of survival prolongation. The principle 
of equipoise in clinical trials means that an adequately designed treatment trial is a trial that 
tests a new or modified form of therapy that is not known to have that benefit. Otherwise the 
trial would not be justified. On the other hand, subjects who participate in clinical trials have 
certain advantages, such as access to standardized protocols with consistent guidelines for 
dosing and toxicity modification and access to potentially better therapies and less expensive 
agents, since the agent itself is usually provided at no cost to the patient, and access to 
professionals and multidisciplinary teams with more expertise in the unique challenges that 
AYAs face.41 Clinical trials require precise tumor evaluations at initial staging and during/
after treatment, as well as respect of time-lines of therapy administration and toxicity 
evaluation and reporting. The oversight and monitoring of trial patients creates a more 
assiduous environment for all patients. These advantages are of particular value to AYAs 
who have more limited financial resources and caregivers in their local community with less 
experience in managing the trials and tribulations of AYAs.
Recent studies have suggested that effective evidence-based treatment strategies generated in 
AYA treatment trials may not be rapidly adopted by oncologists.42 In ALL where the 
evidence is most abundant, only 31% of AYA patients in the greater San Francisco Bay area 
received a demonstrably superior pediatric type of regimen during 2008–2012, and the rate 
declined thereafter to 21%.42 Adult facilities treating ≥ 2 AYA ALL patients per year 
captured in the region were statistically significantly more likely to administer a pediatric 
regimen than lower volume centers, further indicating the importance of referral patterns.42 
Ongoing efforts within NCORP are seeking to further understand factors associated with 
delayed or limited implementation of effective treatment strategies in AYAs.
Fortunately, NCI-designated cancer centers are evaluating their own AYA referral patterns 
and clinical trial determinants43 and inter-group efforts are under way within the current 
organizational structure of the federal clinical trials enterprise, including the NCTN, to 
create novel opportunities for collaborative AYA oncology research among the pediatric and 
adult NCTN groups.44,45 Also, a most recent analysis in the United Kingdom documents 
that sub-groups of AYA patients with advanced solid tumors derive considerable benefit 
from participating in trials involving novel therapeutics.46 As also noted in England, 
however, age-specific biology, pharmacology, proteomics, genomics, clinician and patient 
behavior studies embedded within clinical trials are required to further improve survival for 
AYAs.47
5 | CONCLUSIONS AND RECOMMENDATIONS
Table 2 is a summary of recommendations that can potentially improve accrual of AYAs to 
treatment trials. Most of these have been proffered in prior publications and discussed at 
workshops.49–54 It is time to pursue these suggestions more vigorously in order to 
Bleyer et al. Page 7
Pediatr Blood Cancer. Author manuscript; available in PMC 2018 August 06.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
accomplish in older AYAs what has recently been successful in 15–19 year olds with cancer 
and in children with cancer before that and in whom virtually all progress emanated from 
research. As reviewed, many factors contribute to lack of participation of AYA patients with 
cancer in clinical trials. Yet, other countries have been able to overcome many of the 
limitations.55 American AYAs with cancer deserve better.
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Abbreviations:
ACA Patient Protection and Affordable Care Act
ALL acute lymphoblastic leukemia
AML acute myelogenous leukemia
APC Average percent change
AYA adolescent and young adult
CI confidence interval
CML chronic myelogenous leukemia
COG Children’s Oncology Group
CTEP NCI Cancer Therapy Evaluation Program (CTEP)
FDA Food and Drug Administration
NCI National Cancer Institute
NCORP National Community Oncology Research Program
NCTN National Cancer Treatment Network
SEER Surveillance, Epidemiologyand End Results
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Highlights
• AYA patients with cancer in the United States have had since 1980 a slower 
rate of survival improvement and mortality reduction than those with cancer 
in younger and older age groups.
• Survival prolongation and mortality reduction in patients with cancer is 
directly correlated with clinical trial activity and apparent at all ages.
• AYA patients with cancer have had the lowest participation rate in clinical 
trials than any other age group.
• Even worse, AYAs have had, since 2010, a steady decline in accrual to 
treatment trials sponsored by National Cancer Institute.
• Moreover, clinical trial accruals have their all-age nadir at precisely the peak 
age prevalence of AYA cancers.
• The slower rate of survival improvement and mortality reduction is associated 
with, and a likely resultant of, their low participation rate in clinical trials and 
lack of tissue specimens for research.
• The problem is particularly obvious in 20–29 year olds with acute 
lymphoblastic leukemia, who have had little to no improvement in the 5-year 
survival rate since 1989.
• In order to reverse the accrual trend, multiple changes are necessary, 
including convincing community oncologists to pursue clinical trials on 
behalf of their AYA patients.
• Also the new National Cancer Treatment Network and National Community 
Oncology Research Program and the Food and Drug Administration should 
lead a coordinated attack to eliminate the accrual gap.
• Other solutions include broader health insurance availability for AYAs and 
coverage of clinical trials. Increased availability of clinical trials specifically 
for AYAs with cancer.
• Pediatric and adult oncologists should establish a mutual goal that was 
achieved in children to have clinical trials become a standard of care for AYA 
cancers.
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FIGURE 1. 
Annual NCI CTEP-sponsored treatment trials accruals of AYAs (age 15–39) during 2000–
2015, by calendar year and 5-year age interval. A. All clinical trials except for AIDS-related 
malignancies (and infections during 2014–2015). B. ALL treatment trials. Accrual data 
kindly provided by Nita Seibel and Shanda Finnegan, CTEP, NCI
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FIGURE 2. 
A. Accruals to treatment trials sponsored by National Cancer Institute (NCI)-sponsored 
cooperative groups and NCI-designated cancer centers (black curve) and proportion of all 
cancer accounted for by 14 cancers with peak age proportion during AYA years during 
(purple curve), 2000–2014, by single year of age. B. Ratio of accruals to proportion of the 
14 cancers of all cancer (red curve). Accrual data source is the same as in Figure 1. Data on 
the proportion of all cancer were obtained from incidence data for SEER 18 regions3 and 
from the U.S. Census Bureau for population data5
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FIGURE 3. 
Joinpoint analysis of 5-year leukemia-specific survival of patients with ALL, 2000–2014, 
SEER18, and estimated treatment trial accrual proportion for 2000–2004, by single year of 
age. Joinpoint analysis was performed with the National Cancer Institute Joinpoint 
Regression Program.9 Survival regressions are for 2–17,17–20, and 20–81 years. Accrual 
proportion regressions are for 2–16,16–23, and 23–80 years. P-values refer to the linear 
regression of the corresponding age segment. The inset shows all of the annual data of 
survival rates and accrual proportions as a function of survival with accrual proportion, 
demonstrating a linear regression for accrual proportion values >10%. Accrual data source is 
the same as in Figure 1
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FIGURE 4. 
Annual ALL 5-year leukemia-specific survival, age < 30, 1975–2009, SEER, by 10 year age 
intervals. Joinpoint analysis was performed with the National Cancer Institute Joinpoint 
Regression Program.9 Survival data were obtained from the SEER program.3 APC, average 
annual percent change. Annual values are assessed from two consecutive years (year of and 
year before)
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Table 2
Improving treatment trial accrual of AYAs with cancer
Challenge to treatment trial 
accrual Action to address challenge
Low enrollment in existing 
clinical trials
• Convince community oncologists of the value of clinical trials and the need to pursue clinical trials on 
behalf of their • AYA patients.
• Encourage providers that provide care to AYAs with first cancer symptoms to refer to centers that offer 
clinical trials.
• Increase adoption of National Comprehensive Cancer Network guidelines on referral of AYAs with cancer.
• Facilitate open enrollment of open trials through partnerships between cooperative groups and community 
hospitals.
• Increase AYA organization engagement with patients and patient rights groups to encourage health care 
providers to participate in clinical trials.
Clinical trial availability • Incorporate AYA-specific aims into cooperative group trials.
• For cancers with highly favorable treatment, design new clinical trials with a focus on therapy-related 
toxicities.
• Increase collaboration between pediatric and adult oncologists to design AYA-focused clinical trials for 
cancers common among this group.
Physician-related barriers • Establish an accepted standard of care for AYA cancers among pediatric and adult oncologists.
• Increase financial incentives for collaboration between pediatric and adult oncologists.
Institutional barriers • Increase use of centralized institutional review boards to encourage access and participation in clinical trials.
Societal barriers • Provide health insurance to all AYAs, not just to those less than 25 years of age who are able to continue on the parents’ insurance plan.
• Expand and enforce requirements of the health insurance industry to include coverage of clinical trial costs.
• Empower AYAs to expect their medical providers to discuss clinical trials and arrange contact with clinical 
trial providers.
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